1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Circulating Tumor Cells Market Analysis By Technology (Filtration, Centrifugation, Immunological & Immunomagnetic, Optical, Molecular, Tumor Cell Enrichment & Detection), By Application (Prostate Cancer, Breast Cancer, Colorectal Cancer) and Segment Forec

Global circulating tumor cells market is expected to reach USD 2.28 billion by 2020. Growing prevalence of cancer has heightened the need for effective and early diagnosis. Circulating tumor cells cater to this heightened need and are therefore, expected to witness a surge in demand during the forecast period. Majority of cancer deaths are due to circulating tumor cells and an early diagnosis of the same is expected to increase survival rates. Targeted therapy in cancer has large untapped opportunities and therefore, entails extensive R&D investments aimed at new product development. However, high procedure costs and lack of commercialized products are expected to impede market growth during the forecast period.

Further key findings from the study suggest:

Tumor cell detection was the leading product segment in 2013 primarily owing to the advantages associated with therapeutic monitoring and high procedure prices. Its market is expected to reach an estimated value of over USD 250.0 million by 2020.
Molecular technique emerged as the largest tumor cell detection segment in 2013. This technique holds several advantages over optical tumor cell detection technique and therefore, witnesses higher usage rates. Notable advantages of molecular tumor cell detection techniques include higher sensitivity and high-throughput analysis. Moreover, the introduction of new products such as CellSearch by Janssen Pharmaceutical is expected to drive segment growth.
Tumor cell enrichment is also expected to witness lucrative growth over the next six years. The market is primarily driven by rapidly growing demand for prognostic technologies coupled with the presence of high patient unmet needs.
Immunological and immunomagnetic techniques associated with tumor cell enrichment were the largest market in 2013, accounting for a share of over 50.0%. It is the most commonly used diagnostic technique and therefore, hold high market penetration rates.
North America was the most revenue generating market in 2013. Presence of sophisticated healthcare infrastructure, growing prevalence of cancer and relatively larger presence of commercialized products are some factors attributing to its market position.
The Asia Pacific circulating tumor cells market holds lucrative future growth opportunities. High prevalence of unmet patient needs, constantly improving healthcare infrastructure and increasing healthcare expenditure levels in the emerging markets of India and China are some factors accounting for its market attractiveness.
Some key players of the circulating tumor cells market include AVIVA BioSciences Corporation, Silicon Biosystems S.p.A, Advanced Cell Diagnostics Inc, Celula Inc., Epic Sciences Inc., AdnaGen AG, Vitatex Inc, Rarecells Inc. and Fluxion Biosciences Inc.
For the purpose of this study, Grand View Research has segmented the global circulating tumor cells market on the basis of technology, application and region:

Global Circulating Tumor Cells Technology Outlook (Revenue, USD Million, 2012 – 2020)
- Tumor Cell Enrichment
- Filtration
- Centrifugation
- Immunological and Immunomagnetic
- Tumor Cell Detection
- Molecular
- Optical
Global Circulating Tumor Cells Application Outlook (Revenue, USD Million, 2012 – 2020)
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Others (pancreatic, lung, ovarian cancer)
Circulating Tumor Cells Regional Outlook (Revenue, USD Million, 2012 – 2020)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- Spain
- Asia Pacific
- India
- China
- Japan
- RoW

Table Of Contents

Circulating Tumor Cells Market Analysis By Technology (Filtration, Centrifugation, Immunological and Immunomagnetic, Optical, Molecular, Tumor Cell Enrichment and Detection), By Application (Prostate Cancer, Breast Cancer, Colorectal Cancer) and Segment Forec
Table of Content

Chapter 1. Executive Summary

1.1. Circulating Tumor Cells - Industry Summary and Critical Success Factors (CSFs)

Chapter 2. Circulating Tumor Cells Industry Outlook

2.1. Market Segmentation

2.2. Market Size and Growth Prospects

2.3. Circulating Tumor Cells Market Dynamics

2.3.1. Market Driver Analysis

2.3.2. Market Restraint Analysis

2.4. Key Opportunities Prioritized

2.5. Industry Analysis - Porter's

2.6. Circulating Tumor Cells Market PESTEL Analysis, 2013

Chapter 3. Circulating Tumor Cells Technology Outlook

3.1. Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.2. Tumor Cell Enrichment Technology

3.2.1. Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.2.2.Filtration Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.2.3.Centrifugation Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.2.4.Immunological and Immunomagnetic Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.3. Tumor Cell Detection Technology

3.3.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.3.2. Molecular Market Estimates and Forecasts, 2012 - 2020 (USD Million)

3.3.3.Optical Market Estimates and Forecasts, 2012 - 2020 (USD Million)

Chapter 4. Circulating Tumor Cells Application Outlook

4.1. Market Estimates and Forecast By Application, 2012 - 2020 (USD Million)

4.2. Prostate Cancer

4.2.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million)

4.3. Breast Cancer

4.3.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million)

4.4. Colorectal Cancer

4.4.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million)

4.5. Others

4.5.1.Market Estimates and Forecasts, 2012 - 2020 (USD Million)

Chapter 5. Circulating Tumor Cells Regional Outlook

5.1. North America

5.1.1.Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.1.2.U.S. Market Estimates and Forecast, by Technology, 2012 - 2020 (USD Million)

5.1.3.Canada Market Estimates and Forecasts, by Technology, 2012-2020 (USD Million)

5.1.4.Market Estimates and Forecast, by Application, 2012 - 2020 (USD Million)

5.1.5.U.S. Market Estimates and Forecast, by Application, 2012 - 2020 (USD Million)

5.1.6.Canada Market Estimates and Forecast, by Application, 2012 - 2020 (USD Million)

5.2. Europe

5.2.1.Europe Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.2.2.France Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.2.3.Spain Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.2.4.Germany Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.2.5. Europe Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

5.2.6.France Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

5.2.7.Spain Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

5.2.8.Germany Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

5.3. Asia Pacific

5.3.1.Asia Pacific Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.3.2.India Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.3.3.China Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.3.4.Japan Market Estimates and Forecasts, by Technology, 2012 - 2020 (USD Million)

5.3.5.Asia Pacific Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

5.3.6.India Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

5.3.7.China Market Estimates and Forecasts, by Application, 2012-2020 (USD Million)

5.3.8.Japan Market Estimates and Forecasts, by Application, 2012-2020 (USD Million)

5.4. RoW

5.4.1.RoW Market Estimates and Forecasts, by Technology, 2012- 2020 (USD Million)

5.4.2.RoW Market Estimates and Forecasts, by Application, 2012 - 2020 (USD Million)

Chapter 6. Competitive Landscape

6.1 AVIVA BioSciences Corporation

6.1.1 Company Overview

6.1.2 Financial Performance

6.1.3 Product Benchmarking

6.1.4 Strategic Initiatives

6.2 AdnaGen AG

6.2.1 Company Overview

6.2.2 Financial Performance

6.2.3 Product Benchmarking

6.2.4 Strategic Initiatives

6.3 Celula Inc

6.3.1 Company Overview

6.3.2 Financial Performance

6.3.3 Product Benchmarking

6.3.4 Strategic Initiatives

6.4 Advanced Cell Diagnostics Inc.

6.4.1 Company Overview

6.4.2 Financial Performance

6.4.3 Product Benchmarking

6.4.4 Strategic Initiatives

6.5 Epic Sciences Inc.

6.5.1 Company Overview

6.5.2 Financial Performance

6.5.3 Product Benchmarking

6.5.4 Strategic Initiatives

6.6 Rarecells Inc.

6.6.1 Company Overview

6.6.2 Financial Performance

6.6.3 Product Benchmarking

6.6.4 Strategic Initiatives

6.7 Fluxion Biosciences Inc

6.7.1 Company Overview

6.7.2 Financial Performance

6.7.3 Product Benchmarking

6.7.4 Strategic Initiatives

6.8 Silicon Biosystems S.p.A

6.8.1 Company Overview

6.8.2 Financial Performance

6.8.3 Product Benchmarking

6.8.4 Strategic Initiatives

6.9 Vitatex Inc

6.9.1 Company Overview

6.9.2 Financial Performance

6.9.3 Product Benchmarking

6.9.4 Strategic Initiatives

Chapter 7. Methodology and Scope

7.1. Research Methodology

7.2. Research Scope and Assumption

7.3. List of Data Sources


List of Tables

1. Circulating Tumor Cells - Industry Summary andCritical Success Factors (CSFs)
2. Global Circulating Tumor Cells Revenue, 2012 - 2020
3. Global Circulating Tumor Cells Market Revenue By Region, (USD million), 2012 - 2020
4. Global Circulating Tumor Cells Market Revenue by Technology, (USD million), 2012 - 2020
5. Global Tumor Cell Enrichment Technology Market, 2012 to 2020 (USD million)
6. Global Filtration Market, 2012 to 2020 (USD million)
7. Global Centrifugation Market 2012 to 2020 (USD million)
8. Global Immunological and Immunomagnetic Market 2012 to 2020 (USD million)
9. Global Tumor Cell Enrichment Market, 2012 to 2020 (USD million)
10. Global Molecular Market, 2012 to 2020 (USD million)
11. Global Optical Devices Market, 2012 to 2020 (USD million)
12. Global Circulating Tumor Cells Market Revenue by Application, (USD million), 2012 - 2020
13. Global Prostate Cancer Market, 2012 to 2020 (USD million)
14. Global Breast Cancer Market, 2012 to 2013 (USD million)
15. Global Colorectal Cancer Market, 2012 to 2013 (USD million)
16. Global Other Cancer Market, 2012 to 2013 (USD million)
17. Global Circulating Tumor Cells Market, By Region, 2012 to 2020 (USD million)
18. North America Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
19. U.S. Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
20. Canada Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
21. Europe Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
22. Germany Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
23. France Circulating Tumor Cells demand, by Technology , (USD million), 2012 - 2020
24. Spain Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
25. Asia Pacific Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
26. India Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
27. Japan Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
28. China Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
29. RoW Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
30. Brazil Circulating Tumor Cells demand, by Technology, (USD million), 2012 - 2020
31. North America Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
32. U.S. Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
33. Canada Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
34. Europe Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
35. Germany Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
36. France Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
37. Spain Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
38. Asia Pacific Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
39. India Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
40. Japan Circulating Tumor Cells demand, by Application,(USD million), 2012 - 2020
41. China Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
42. RoW Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
43. Brazil Circulating Tumor Cells demand, by Application, (USD million), 2012 - 2020
44. Global Circulating Tumor Cells Market - Competitive Landscape


List of Figures

1. Circulating Tumor Cells Market Segmentation
2. Global Circulating Tumor Cells Market Revenue, 2012 - 2020
3. Circulating Tumor Cells Market Dynamics
4. Circulating Tumor Cells Company Market Share Analysis, 2012
5. Key Opportunities Prioritized
6. Industry Analysis - Porter's
7. Circulating Tumor Cells PESTEL Analysis, 2012
8. Global Circulating Tumor Cells Market, by Technology, (USD million), 2012 - 2020
9. Global Tumor Cell Enrichment Market, by region 2012 to 2020 (USD million)
10. Filtration Market, by Region, (USD million), 2012 - 2020
11. Centrifugation Market, by Region, (USD million), 2012 - 2020
12. Immunological and Immunomagnetic Market, by Region, (USD million), 2012 - 2020
13. Global Circulating Tumor Cells Market, by Application, (USD million), 2012 - 2020
14. Prostate Cancer Market, by Region, (USD million), 2012 - 2020
15. Breast Cancer Market, by Region, (USD million), 2012 - 2020
16. Colorectal Cancer Market, by Region 2012 to 2020 (USD million)
17. Other Cancer Market, by Region 2012 to 2020 (USD million)
18. Circulating Tumor Cells Market - Company Market Share Analysis, 2013 (%)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.